Background {#Sec1}
==========

Cancer is a leading cause of morbidity and mortality in Canada. In addition to human suffering, cancer annually costs the health system an estimated C\$4 billion and is the largest contributor to lost economic productivity \[[@CR1]\]. This trend will not abate, with incident cases in British Columbia (BC) expected to increase by 57 % between 2012 and 2030 \[[@CR2]\]. Providing high-quality care to patients that is also cost-effective is an ongoing challenge for cancer control. Policymakers face the challenge to control cost as increases in health care spending put pressure on other government priorities such as education and defense. Since labor costs account for 15 % of health care budgets in Canada \[[@CR3]\], payers are exploring how they might contain costs by critically evaluating the way physicians are paid and how changes in payment method will affect health outcomes, resource utilization, and quality of care.

Physicians are tasked to deliver care that maximizes patient benefit. Information asymmetry in medical treatment requires principals (e.g., third-party payers; patients) to rely on agents (e.g., physicians) to recommend and communicate the consequences of alternative courses of action \[[@CR4]\]. Agents must be incentivized to maximize benefits to patients, rather than solely to the agent's own benefit. In their most basic form, financial incentives from remuneration are created through transferring money from the principals to the agent to provide care at a specified level of quality. Economic theory suggests that incentives may be used to reduce the marginal cost of physician behavior change, e.g., increasing adherence to evidence-based guidelines \[[@CR5]\]. If the size of the monetary incentive is greater than the cost for the physician changing their behavior, the profit (or portion thereof) may be used as a reward to the physician. The magnitude of change and direction of behavioral response (i.e., incentive vs. disincentive) will depend on a number of factors, including the characteristics of the incentive payment method and the financial and opportunity costs of participating in incentive schemes. These factors are important because poorly designed incentives may have unintended behavioral effects and lead to lower levels of quality, e.g., if an overly large payment wrongly signals high risk \[[@CR6]\].

Major payment methods {#Sec2}
---------------------

There are two primary attributes of physician remuneration that influence the magnitude and direction of physician behavior response: method of payment and level of payment \[[@CR7]\]. Payment methods include capitation, fee-for-service, performance-based payment, prospective payment, and/or salary. The timing of the payment can be prospective, i.e., set in advance according to a fixed budget, or retrospective with or without a cap on total payments that are made.

The second attribute, payment level, may be fixed in advance or subject to negotiation after care is delivered. Alternatively, physicians may have complete or partial discretion as to the amount of money charged for services. The amount of payment for physician services may be reduced or withheld if behavior does not conform to benefit-maximizing requirements. Finally, the amount may vary depending on characteristics of the provider or patients seen (e.g., more complex cases receive higher payments). Table [1](#Tab1){ref-type="table"} provides an overview of each category of payment method, including the terms associated with the payment approach, the definition of each category and the potential benefits and harms of the payment approaches.Table 1Overview of physician payment approachesPayment modelDefinitionPotential benefits and harmsCapitation; pre-paymentProviders are paid a set amount for each person enrolled with them regardless of whether the person receives care.May reduce unnecessary health services utilization since payment is not tied to service provision. It is argued the financial incentives in capitation will lead primary care physicians to reduce referrals to specialists \[[@CR12]\]. However, some argue that providers may be incentivized to develop overly long lists and actually refer to specialist care too frequently \[[@CR33]\].Fee-for-serviceProviders are paid separately for all medical services deliveredIn this method, providers are reimbursed for all medical services they provide, lowering the risk of taking on patients who need many services. However, appointments may be limited to one service and complicated patients may require many appointments. This method may also increase the use of services which can give diminishing marginal returns or even have detrimental effects \[[@CR33]\] and incentivize the over-delivery of care because it rewards increases in service volume, regardless of health benefit \[[@CR11]\].Pay for performance; payment by results; performance-based payment; results-based purchasing; value-based purchasing; target paymentsProviders receive different payments for meeting or missing performance benchmarks, e.g., related to quality, efficiency, care integration \[[@CR8]\].Incentives based on achieving quality objectives are expected to be associated with behaviors designed to achieve the quality targets, e.g., immunization rates, mammography screening, patient satisfaction scores \[[@CR16]\]. Risk adjustment algorithms should be employed so that organizations are not penalized for treating sicker patients.Prospective payment; activity-based funding; bundled payment; lump-sum payment; block funding; clinical pathwaysA fixed payment for each patient, based only on the patient's diagnosisMay reduce clinical variation and end-of-life costs \[[@CR40]\]. However, without a focus on quality measurement, the pressures of these systems may place perverse incentives on providers to deliver less care \[[@CR51]\]. The development of "clinical pathways" (management plans that address quality by providing the sequence and timing of actions covered by the associated lump sum payment \[[@CR55]\]) aims to address this issue.SalaryIndividual providers get a fixed fee per year regardless of the number of patients they treatSimilar to capitation, this method may have utilization lowering effects. However, care quality may be compromised if providers respond to fixed payment by working shorter hours and being less responsive to their patients' needs and demands \[[@CR56]\].

In the United States (US), most recent reforms aiming to change the way health care is funded have focused on hospital payment, for example using global budgets, shared savings programs, penalties for readmissions, and hospital-acquired conditions, rather than changing the way providers are paid \[[@CR8]\]. However, the 2015 Medicare Access and CHIP Reauthorization Act offers Medicare patients' physicians a choice of payment models, e.g., participating in the Merit-Based Incentive Payment System, which starting in 2019 will adjust a provider's fee-for-service reimbursement up or down based on provider performance on quality measures that are currently being developed \[[@CR9]\]. In Canada, activity-based funding for hospitals have been implemented in at least three provinces, with most physicians receiving some form of blended payment, followed by fee-for-service \[[@CR10]\].

Payment method impacts {#Sec3}
----------------------

The impacts of provider payment methods have been extensively evaluated. For example, researchers have found some correlation between the fee-for-service payment model and increased use of tests \[[@CR11]\]. They note that higher service use does not necessarily improve outcomes and may even be harmful. Changes from fee-for-service to capitated payment models have also been studied several times. This change does not appear to cause problematic decreases in primary care access \[[@CR12]\], but does not decrease hospital use \[[@CR13]\].

The use of prospective payment may increase the rate of hospital readmissions and adverse events, but this increase is related to hospitals assigning more severe diagnoses to patients under prospective payment than they would under other systems \[[@CR14]\]. This means that the hospital is allocated more funding, although direct treatment costs have not increased.

Cash bonuses have been demonstrated to improve some outcomes---vaccination rates, for example---but researchers caution that the improvement observed may be due to better reporting rather than true practice change \[[@CR15]\]. The research indicates that combining payment model changes with other interventions such as educational campaigns may be needed to make meaningful practice changes \[[@CR15]\].

Provider payment reforms such as accountable care organization (ACO) shared savings programs encourage providers to form groups and assume responsibility for the care of a population of patients in order to share in payer savings if quality and cost performance benchmarks are achieved. However, a 2001 study found that forming these groups had no significant effect on factors such as improved care coordination and innovation. The authors hypothesized that this may be because the groups did not identify as cohesive entities and used the structure mainly for legal purposes rather than to improve care provision \[[@CR16]\].

Broadly, existing evidence suggests that changes in physician behaviors have the potential to impact the cost and quality of care provided. Payment method can also influence recruitment and retention of physicians, which in turn impacts patient access and quality of care \[[@CR17]\].

Object of the document {#Sec4}
----------------------

Previous reviews \[[@CR18]--[@CR21]\] have evaluated the impact of different payment methods on cost and quality of care, but none have focused specifically on the cancer care context. Across Canada, oncology remuneration takes several different forms. Sourced from the 2013 National Physician Survey \[[@CR22]\], Fig. [1](#Fig1){ref-type="fig"} shows that salary is the most common remuneration method for medical oncologists (37.7 % of respondents); other methods reported are fee-for-service (17.8 %), "sessional/per diem" (3.9 %), none of these (1.2 %), and a blend of these methods (32.4 %). No oncologists reported payment by capitation or "incentives and premiums".Fig. 1Medical oncologist responses to 2013 National Physicians Survey \[[@CR22]\] question 6a on remuneration method (percentage of total)

The objective of this study is to undertake a rapid review of the literature---a database search combined with a hand search of several systematic reviews and the gray literature---to explore the impact of physician payment methods on patient outcomes, care quality, and overall expenditure, with a specific focus on cancer control in Canada.

Methods {#Sec5}
=======

We followed guidelines for performing a rapid literature review \[[@CR23]\], which included defining eligibility criteria, identifying a search strategy, performing study selection according to the eligibility criteria, and abstracting data; this was followed up by an ancillary search for special topics. These searches were conducted in June 2015.

Eligibility criteria {#Sec6}
--------------------

We set out to include all studies published in English published in the past 10 years, regardless of whether they were original analyses or reviews of past work. We defined "impact" as the consequences of physician payment methods on health services use, expenditures, health outcomes, physician retention, and stakeholder opinion. We excluded abstracts, editorials, letters, and news.

Search strategies {#Sec7}
-----------------

We worked with a senior librarian at the BC Cancer Agency to help identify subject headings and keywords. We also identified search terms and keywords from key background articles.

Studies were identified through bibliographic searches of the MEDLINE, Embase, and Evidence Based Medicine Reviews publication databases using the following terms and variations upon these:PhysiciansOncologyNeoplasmActivity-based fundingProspective paymentBundled paymentLump-sum paymentPay for performancePayment by resultsPerformance based paymentResults-based purchasingValue-based purchasingTarget paymentsCapitationPre-paymentSalaryFee-for-service

Under the guidance of the librarian, we undertook an iterative process to customize and refine the search strategy. Table [2](#Tab2){ref-type="table"} presents the full search strategies for each database. Although the strategies contain statements that emphasize results specific to Canada, these are combined with other statements that use "or"; as such, the search has no regional limitation.Table 2Search strategies by databaseMEDLINE1 payment by results.mp.1322 activity based funding.mp.343 prospective payment.mp.24714 results based purchasing.mp.05 pay for performance.mp.13886 value based purchasing.mp.4067 performance based payment.mp.328 Value-Based Purchasing/2219 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8437610 (salar\* or cash or funding or remunerat\* or reimburs\* or capitation).m_titl.10,33111 exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/19,94312 exp "Fees and Charges"/14,26513 economics, medical/or fees, medical/or exp Economics, Dental/411914 exp Income/30,58715 "costs and cost analysis"/17,76316 exp models, economic/941517 9 or 10 or 11 or 12 or 13 or 14 or 15 or 1691,62018 Physician Incentive Plans/168619 exp Physicians/ec \[Economics\]290120 economics, medical/or fees, medical/330821 Physician's Practice Patterns/38,53222 "episode of care"/131423 Patient Care Bundles/5324 (physician\* adj3 (remunerat\* or reimburs\* or payment\*)).mp. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]108225 exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/19,94326 exp health personnel/ec862227 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 2670,14028 exp Neoplasms/1,465,61629 medical oncology/or radiation oncology/12,92130 exp Antineoplastic Agents/503,15431 Cancer Care Facilities/277232 Oncology Nursing/or Oncology Service, Hospital/618633 (cancer\* or oncolog\* or chemotherap\* or radiotherap\* or radiation therap\*).m_titl.549,42934 28 or 29 or 30 or 31 or 32 or 331,800,02335 17 and 27 and 3498336 exp Canada/77,34537 (canad\* or british columbia or alberta or ontario or quebec or manitoba or saskatchewan or nova scotia or new brunswick or newfoundland or prince edward island).mp. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\]118,54038 36 or 37118,68039 27 and 34 and 3828540 9 and (10 or 11 or 12 or 13 or 14 or 15 or 16) and 27 and 344741 9 and 27 and 345042 9 and 349943 9 and 27 and 383944 9 and 34 and 38445 39 or 40 or 41 or 42 or 43 or 4441946 limit 45 to yr = "2005 -Current"28647 limit 46 to english language275EmbaseEmbase \<1974 to 2015 May 14\>\#Search statementResults1payment by results.mp.2532activity based funding.mp.583prospective payment.mp.87244results based purchasing.mp.05pay for performance.mp.18596value based purchasing.mp.3207performance based payment.mp.438Value-Based Purchasing/281091 or 2 or 3 or 4 or 5 or 6 or 7 or 813,74210(salar\* or cash or funding or remunerat\* or reimburs\* or capitation).m_titl.18,83511exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/55,98112exp "Fees and Charges"/35,17113economics, medical/or fees, medical/or exp Economics, Dental/651,97814exp Income/71,06115"costs and cost analysis"/53,72116exp models, economic/115,183179 or 10 or 11 or 12 or 13 or 14 or 15 or 16857,40918Physician Incentive Plans/51,52219exp Physicians/ec \[Economics\]020economics, medical/or fees, medical/45,65321Physician's Practice Patterns/183,69922"episode of care"/209,40323Patient Care Bundles/18824(physician\* adj3 (remunerat\* or reimburs\* or payment\*)).mp. \[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword\]589625exp reimbursement mechanisms/or exp fee-for-service plans/or exp prospective payment system/55,98126exp health personnel/ec02718 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26506,04428exp Neoplasms/3,504,87929medical oncology/or radiation oncology/108,56330exp Antineoplastic Agents/1,565,42931Cancer Care Facilities/19,45832Oncology Nursing/or Oncology Service, Hospital/25,47633(cancer\* or oncolog\* or chemotherap\* or radiotherap\* or radiation therap\*).m_titl.1,058,6033428 or 29 or 30 or 31 or 32 or 334,403,4633517 and 27 and 3412,76636exp Canada/136,39837(canad\* or british columbia or alberta or ontario or quebec or manitoba or saskatchewan or nova scotia or new brunswick or newfoundland or prince edward island).mp. \[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword\]228,0773836 or 37228,0773927 and 34 and 381648409 and (10 or 11 or 12 or 13 or 14 or 15 or 16) and 27 and 34367419 and 27 and 34382429 and 34554439 and 27 and 38118449 and 34 and 38144539 or 40 or 41 or 42 or 43 or 44230446limit 45 to yr = "2005 -Current"183347limit 46 to english language178848"health policy economics and management".ec.504,3664947 and 4841650(physician\* and (fee or fees or pay\* or remunerat\* or compensat\* or purchas\* or reimburs\*)).m_titl.237251limit 50 to (english language and yr = "2005 -Current")6945249 or 51110453limit 52 to yr = "2013 -Current"2915447 and physician\*.mp. and (fee or fees or pay\* or remunerat\* or compensat\* or purchas\* or reimburs\*).mp. \[mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword\]1515552 or 54117756limit 55 to exclude medline journals855753 or 5635258remove duplicates from 57342EBM ReviewsEBM Reviews - Cochrane Database of Systematic Reviews \<2005 to December 2014\>\#Search statementResults1(Cochrane Effective Practice and Organisation of Care Group).mp. \[mp = title, short title, abstract, full text, keywords, caption text\]9121 and (canad\* or british columbia).ti, kw.031 and (cancer\* or oncolog\* or neoplasms or tumor\* or tumour\* or chronic).ti,kw.341 and (physician\* or specialit\* or specialt\* or dentist\* or cost\* or financ\* or econom\* or fees or reimburs\* or pay\* or salar\* or remunerat\* or fund\* or cash or incentive\*or bundle\* or performance or capitation or pattern\* or episode\*).ti, kw.255remunerat\*.ti, kw.163 or 4 or 528

Gray literature search {#Sec8}
----------------------

We also undertook a gray literature search. This was limited to oncology in Canada for time and scope reasons. We searched abstracts contained in the Canadian Health Human Resources Network online library \[[@CR24]\], as well as websites for the following organizations:Canadian Association of Medical Oncologists \[[@CR25]\]Canadian Association of Radiation Oncologists \[[@CR26]\]Canadian Foundation for Healthcare Improvement \[[@CR27]\]Canadian Institute for Health Information \[[@CR28]\]Institute for Clinical Evaluative Sciences \[[@CR29]\]National Physicians Survey \[[@CR22]\]Statistics Canada \[[@CR30]\]

Study selection and data abstraction {#Sec9}
------------------------------------

One reviewer conducted screening. Initially, we reviewed article titles and abstracts for relevance; the full text of articles that appeared to be potentially eligible were subsequently reviewed for inclusion. EM abstracted the following data from each included article: authors, publication date, country, title, payment approach, health issue, outcomes measured, research methods, and study findings. We worked closely with a senior librarian who helped design and calibrate the search strategies presented in full in Table [2](#Tab2){ref-type="table"}. In-duplicate data extraction and post hoc data extraction review were not performed. We encourage future reviews of this literature body that employ full systematic review methods to include these activities.

Study acquisition flow {#Sec10}
----------------------

Figure [2](#Fig2){ref-type="fig"} presents the acquisition flow of included studies from the database search. Of 711 citations identified by the database search, ten addressed the impact of physician payment methods on quality or access to care, equity, cost, or efficiency in the context of oncology. Although we are specifically interested in the effect of payment methods in the Canadian context, the relative paucity of studies encouraged us to include research conducted outside Canada. Barring major contextual differences, payment method effects should be similar across jurisdictions. Additional file [1](#MOESM1){ref-type="media"} contains our populated PRISMA checklist.Fig. 2Study acquisition flow from database search

Results {#Sec11}
=======

This section reviews the findings of the articles returned by the database search and the ancillary search. A subsection highlights the research methods used to evaluate the consequences of physician payment methods.

Study characteristics {#Sec12}
---------------------

Table [3](#Tab3){ref-type="table"} presents the key characteristics of the database search articles according to geographical location of study, study design, sampling method, and sample size. The majority of included articles were from the US and three studies were from Canada. Study designs included a mix of quantitative and qualitative approaches, including observational studies (using administrative databases) \[[@CR6], [@CR12]--[@CR14], [@CR31], [@CR32]\], literature reviews \[[@CR11], [@CR33]--[@CR36]\], semi-structured interviews \[[@CR37]\], and collection survey \[[@CR15], [@CR38]--[@CR40]\]. Table [4](#Tab4){ref-type="table"} shows which payment methods each article discusses.Table 3Characteristics of the identified articles from the database searchCharacteristicNumber of articlesGeographic location Canada2 China1 Denmark0 Norway0 South Africa0 USA7Study design Literature review/commentary4 Qualitative survey/interviews3 Statistical analysis3 (regression analysis)Sampling method Random0 All who agreed to participate and were eligible6 Not applicable4Sample size \<1003 100 \< *n* \< 10001 \>10002 Not applicable4Table 4Payment methods discussedThe shaded area indicates that the article in a given row discusses the payment method listed in the corresponding column header

Articles identified from the database search {#Sec13}
--------------------------------------------

Table [5](#Tab5){ref-type="table"} summarizes the key attributes of the ten articles identified through the database search examining physician remuneration in oncology. Four articles \[[@CR11], [@CR35], [@CR36], [@CR41]\] are based on literature reviews or commentary. As such, the findings may not be unique to the article.Table 5Database search articlesAuthorsTitlePayment approachMethodsHealth issueOutcomes measuredFindingsBailes JS and Coleman TS. 2014 (USA)The long battle over payment for oncology services in the office setting \[[@CR35]\]Fee-for-serviceReviews Medicare policy history and reports expert opinionOutpatient ChemotherapyPhysician fees for chemotherapy drugsPayments for drug administration can be much less than its cost. Marginal revenue from drug payments is used to make up the difference, and drug payment decreases could result in provider losses.Bekelman JE, Epstein AJ and Emanuel EJ. 2014 (USA)Getting the next version of payment policy "right" on the road toward accountable cancer care \[[@CR11]\]Fee-for-service vs. prospective paymentReviews published literature and agency documentationCancer careChanges in costs and outcomesProspective payment systems should include performance measurement to counter associated perverse incentives. For complex cases lump sum payment could be combined with fee-for-service.Elit, L. 2006 (Canada)An analysis of alternative funding for physicians practicing gynecologic oncology in Ontario, Canada prior to 2001 \[[@CR36]\]Fee-for-serviceLiterature search, discussion with stakeholders, meeting minutes from groups considering alternate funding systemsGynecologic cancerEvents preceding reform of the funding agreement with gynecologic oncologistsFee-for-service does not account for the increased complexity of services on cancer patients, causing losses and making recruitment and retention difficult.Elit L, Cosby J and Gynecologic Oncology Group in Ontario. 2006 (Canada)Does shifting a physician payment system shift physician priorities? A multi-site evaluation of an alternative payment plan (APP) for gynecologic oncologists in Ontario \[[@CR37]\]Fee-for-service vs. a negotiated arrangement where contracts are made with physician groups who are paid a fixed amount regardless of productivityInterviews with 14 Ontario gynecologic oncologists; interviews were analyzed using grounded theory.Gynecologic cancerChanges in physician behavior in response to the new payment systemThe new plan improved quality of life and income predictability, increased preventive health care work. Vacancies were filled and staff were retained. Staff delegated follow-up with less complicated patients. The plan did not reduce workload.Greenapple R. 2013 (USA)Rapid expansion of new oncology care delivery payment models: results from a payer survey \[[@CR40]\]Comparing "clinical pathways" (bundled payments with quality management), capitation, shared savings and pay-for-performanceA validated survey of payers representing more than 100 million individuals that asked payers about models of care that could improve quality and reduce costs.Cancer carePayer perceptions of which payment models are most effectivePayers believe that clinical pathways can reduce clinical variation in care, improve quality and reduce costs, mainly by reducing end-of-life costsHabermann EB, Virnig BA, Riley GF, and Baxter NN. 2007 (USA)The Impact of a Change in Medicare Reimbursement Policy and HEDIS Measures on Stage at Diagnosis Among Medicare HMO and Fee-For-Service Female Breast Cancer Patients \[[@CR31]\]Fee-for-service vs. health maintenance organization (capitation)Compares the effect of change from biennial to annual mammograms by payment method.Breast cancerSurveillance Epidemiology and End Results, Medicare claims databaseWomen enrolled in the health maintenance organization were more likely than those in fee-for-service to be diagnosed early both before and after the, but after the change, the disparity shrank from 4.7 to 2.3 %.Kuo RN, Chung KP and Lai MS. 2011 (China)Effect of the pay-for-performance program for breast cancer care in Taiwan \[[@CR40]\]Fee-for-service/activity-based funding vs. pay-for-performance (encouraging evidence-based therapy and reward better patient outcomes)A retrospective analysis of patients who received curative surgery. Multivariate regression analyzed the association between program enrollment and quality of care.Breast cancerPopulation-based cancer registration and claims dataEnrollees received higher-quality care, had better 5-year overall survival and less recurrenceMakari-Judson G, Wrenn T, Mertens WC, Josephson G and Stewart JA. 2014 (USA)Using Quality Oncology Practice Initiative Metrics for Physician Incentive CompensationPay for performanceBased on their performance in five achievement categories, physicians were offered a bonus percentage of salary corresponding to the target level achieved.Hematology oncologyWork relative value units, Quality Oncology Practice Initiative metrics, patient emotional well-being from medical records, academic goals and the overall financial success of the groupResults are reported for two measures: quality and emotional well-being. For the former, "Tier III" was achieved resulting in a bonus of 24 % salary. For the latter no bonus was achieved.Newcomer LN, Gould B, Page RD, Donelan SA and Perkins M. 2014 (USA)Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment ModelFee-for-service vs. episode payments (bundled payments)Physicians at five medical oncology groups were reimbursed with a single episode payment for services to cancer patients as part of a pilot program. The episode cohort was compared with a control fee-for-service cohort.Breast, colon and lung cancerClinical data corresponding to characteristics of episode payments (cancer type, stage, genetic profile), claims data, average chemotherapy drug sale priceThe total medical cost for the episode cohort was \$33.4 million less than what was predicted using fee-for-service.Patel KK, Morin AJ, Nadel JL and McClellan MB. 2013 (USA)Meaningful Physician Payment Reform in OncologyClinical pathways (bundled payments), pay for performance, fee-for-serviceReviews pilot initiatives in the US that combine physician payment reforms with delivery reforms.Cancer careResearch on oncology practice and the impact of physician payment methods, proposals from oncology societiesThe authors propose a payment model that combines fee-for service payment with case management payment and a care coordination fee, increasing total provider payment but potentially decreasing the total care cost.

Habermann et al. \[[@CR31]\] used data from the Medicare cancer registry (part of the National Cancer Institute's Surveillance Epidemiology and End Results project) to compare breast cancer screening rates in health maintenance organizations (HMOs) with rates for providers reimbursed by fee-for-service. (Physicians practicing in HMOs are normally reimbursed through capitation \[[@CR42]\]). Health maintenance organizations and managed care generally tend to use more resources at the beginning of the care process, e.g., performing preventive care, in order to keep people healthier and also save money in the long run \[[@CR43]\]. Cancer stage at diagnosis, a proxy for screening rate, was estimated using a logistic regression model that adjusted for payment method as well as demographic variables. The authors found that women enrolled in health maintenance organizations were more likely than those in fee-for-service to be diagnosed early (and therefore likely to have received screening), both before and after a change from biennial to annual mammograms. However, this difference decreased by half after the move to annual screening.

Elit \[[@CR36]\] analyzed the events that led to a change in payment method for Ontario-based gynecologic oncologists by conducting a non-systematic search of academic and gray literature and also speaking to key stakeholders including university physicians and members of the Ontario Medical Association. She found that most of the province's gynecologic oncologists changed from fee-for-service remuneration to the salary-based program offered in 2001 because they reported that prices in Ontario's fee-for-service payment model did not account for the fact that non-oncology procedures are often more costly when performed on cancer patients. Study participants noted that the situation had encouraged specialists to focus on uncomplicated cases. Under-reimbursement had also hampered the recruitment and retention of specialized staff, but retention was improved when the alternative program of salary payment was offered.

In a related study, Elit and Cosby \[[@CR37]\] conducted qualitative interviews which explored the impact on gynecologic oncologists of switching from fee-for-service to the alternative salary-based plan described above. They recruited 14 gynecologic oncologists from five practice sites in Ontario, four of which had opted for the change from fee-for-service to salary. A semi-structured interview guide designed for the study was used in the interviews; it consisted of professional and personal questions. The interviewed physicians who experienced the remuneration change reported improvements in their own quality of life and income predictability, while also noting that their preventive care work had increased. They noted that practice site vacancies were able to be filled and staff were able to be retained. It had been hoped that the new program would also reduce physician workload, but the interviewees stated this had not occurred. However, interviewees affirmed that follow-up for less complicated patients was now being appropriately delegated.

Newcomer et al. \[[@CR44]\] describe a pilot project where physicians at five medical oncology groups in the US were reimbursed with a single episode payment for all breast, colon, and lung cancer patients at their initial visit. All other physician services continued to be reimbursed via the existing fee-for-service contract. The study design compared the operational and control cohorts during the pre-pilot and pilot time periods. In the analysis, 810 patients were used. Data included clinical data corresponding to characteristic of episode payments (cancer type, stage, genetic profile), the total medical cost per episode of care (a linear regression function of the episode payment condition, age, and sex), and chemotherapy drug cost (average sale price). Controls were obtained from UnitedHealthcare's registry of more than 65,000 breast, colon, and lung cancer patients. The net savings in total medical cost for the episode cohort compared to fee-for-service was \$33.4 million. Although the program contained several incentives to lower drug costs, chemotherapy drug spending unexpectedly rose; it totaled \$13.5 million more than predicted at \$21 million. The authors state the study was not sufficiently powered to analyze which expenses disproportionately impacted the differences in total medical cost.

Offering expert commentary on the Medicare program's reimbursement for chemotherapy services, Bailes and Coleman \[[@CR35]\] argue that Medicare's fee-for-service payment system has tended to underestimate the total cost of chemotherapy treatment. The authors state that reimbursement for products and services used in the administration of chemotherapy drugs has often been substantially less than their true cost. To cover the administration resource shortfall, they note that oncologists have relied on marginal profit from drug reimbursement \[[@CR45]\]. Decreases in drug payments brought in by the 2003 Medicare Modernization Act have resulted in losses for some oncologists. However, they note that the 2010 Affordable Care Act includes funding for pilot programs to "align nationally recognized, evidence-based guidelines of cancer care with payment incentives ... in the areas of treatment planning and follow-up care planning" \[[@CR46]\].

Turning to pay for performance, Kuo et al. \[[@CR32]\] conducted a retrospective analysis of breast cancer care examining a program targeted at hospitals which rewards better patient outcomes with a bundled payment, which encompasses treatment options based on recommended treatment plan for the breast cancer stage. This payment is higher than in the original payment scheme (case-based for surgery and fee-for-service for other treatment components) when the treatment plan is followed, lower when it is not. The authors note that attending physicians in Taiwan are mainly employed by hospitals, so financial incentives applied at the hospital level may still directly impact physician behavior. Data came from the Taiwan Cancer Database. Women diagnosed in 2003 or 2004 with stage I or II breast cancer were included. The association of program participation and quality of care was estimated using linear regression and controlling for age, stage, comorbidity, and type of surgery. Results showed that patients treated at hospitals participating in the pay-for-performance program received higher-quality care, achieved better 5-year overall survival, and experienced less recurrence \[[@CR30]\].

Makari-Judson et al. \[[@CR47]\] document the experience of a group of 11 hematologic oncologists who were offered performance-based incentives in five categories (with associated outcome in parentheses): patient-centered goals (measured by the patients' medical record), quality measures (Quality Oncology Practice Initiative metrics), clinical productivity (work relative value units), academic (not specified), and the group's overall financial performance (not specified). Incentives were arranged in three tiers; each corresponded to a category score and triggered a bonus (percentage of salary). The authors report results for two of the five measures: patient-centered goals and quality measures. For the latter, "Tier III" was achieved resulting in a bonus of 24 %. For the former, no bonus was achieved.

Greenapple \[[@CR40]\] conducted an online survey of 49 American health insurers, representing more than 100 million covered individuals, which asked them about the models of care that they are implementing or would support in order to improve cancer care quality and also control cost. The survey results reveal that the payers most favored systems of "clinical pathways", a specialized form of care bundle where an evidence-based algorithm guides care practice for a defined group of patients during a set period of time \[[@CR45]\]. They believe that these could reduce both the cost of end-of-life care and clinical variation in care, while also improving care quality. The payers prioritize controlling costs through the method of reducing wasteful and inappropriate care and believe that clinical pathways are most likely to achieve such reductions.

In an expert commentary, Patel et al. \[[@CR41]\] review pilot initiatives in the US that combine oncologist payment reforms with delivery reforms, including performance incentives, bundled payment and clinical pathways, and mixed methods, i.e., a fee-for-service chemotherapy payment for the cost of buying the drug, fixed payments for drug administration and care management. They propose a physician payment model for cancer care that combines fee-for-service payment with case management payment (to lower the incentive to increase the volume and intensity of patient services) and a care coordination fee. This would involve increasing total payment to physicians but could decrease the total cost of cancer care (by decreasing waste and inefficiency, as well as payments for all other cancer care).

Bekelman et al. \[[@CR11]\] use academic literature and public-sector publications to make evidence-based recommendations on reforms to cancer care payment policy. They argue that any prospective payment systems should focus on performance measurement, since theory predicts that lump sum payment systems will place perverse incentives on providers, e.g., providing too few services to very ill patients \[[@CR6]\]. The authors recommend a strategy of cross-subsidizing with fee-for-service complex cases treated under prospective payment in order to mitigate the risk to providers of having their total costs exceed the lump payment \[[@CR11]\].

Research methods used to evaluate consequences of physician payment methods {#Sec14}
---------------------------------------------------------------------------

Regression analysis was used by two articles in the database search. One used a pretest-posttest study design \[[@CR31]\], where one group is assessed at different time points. The other used a retrospective cohort analysis \[[@CR32]\] where two groups are compared at the same time.

Qualitative research methods were employed by two articles \[[@CR37], [@CR40]\]. Their study designs involved using literature reviews to inform a semi-structured interview guide or surveying payers and conducting in-person interviews with providers. To analyze the qualitative results, Greenapple \[[@CR40]\] calculated the percentage breakdown of participant responses. Two investigators independently analyzed coded data in Elit and Cosby's study \[[@CR37]\]. Then together they discussed themes and developed theory; the model that emerged from the discussion was validated with two final interviews.

Regarding the creditability of study results in general: the studies tended to be exploratory and not designed to provide generalizeable results, but more than two thirds of the articles performed at least some uncertainty analysis of their results.

Data sources used to evaluate consequences of physician payment methods {#Sec15}
-----------------------------------------------------------------------

Since the provider compensation method was often used at the outset as an indicator dividing the sample into cohorts or "treatment groups", studies seldom included payment method as an exogenous variable. Instead study authors compared payment method cohorts using data on utilization and expenditures \[[@CR32]\] and on patient outcomes and stakeholder opinion (collected through in-person interviews and online surveys) \[[@CR37], [@CR40]\].

Results from the gray literature search {#Sec16}
---------------------------------------

Multiple sources provide information on the ways that oncologists are paid in Canada. However, they do not investigate the outcomes associated with the different payments \[[@CR10], [@CR22], [@CR29]\]. For example, the Canadian Institute for Health Information's (CIHI) National Physician Database 2012--2013 \[[@CR10]\] includes payment information for medical specialists, e.g., Fee-for-Service Clinical Payments to Physicians by Province/Territory; oncology is one of the specialties that comprise the medical specialist category.

Discussion {#Sec17}
==========

This review presents the literature's key findings related to the impact of different physician payment methods and uncovers articles that examine those impacts in the context of cancer care. This is important since the study findings show that payment method impacts on cancer care can run contrary to what would be expected in other disease areas. For example, although Ellis \[[@CR6]\] showed that providers reimbursed via fee-for-service are unlikely to discriminate for patient illness severity, Elit \[[@CR36]\] saw that oncologists reimbursed through fee-for-service methods were substituting toward patients with less complicated conditions since the fee levels were not sufficient for treating cancer patients.

The Medicare program has been a leader in experimenting with models of physician payment, but it has not focused on the area of cancer care \[[@CR48]\]. Indeed this review appears to be one of the first treating the impact of physician payment methods on cancer care. Its findings emphasize the importance of further study of the impacts of changing payment methods for the physicians who focus on cancer care. The gray literature search shows that the CIHI National Physician Database includes oncologist remuneration information by province in Canada and could be used as data source for future projects.

Cancer care tends to include high costs concentrated at the end of life, when relatively low-cost palliative care may be a more effective option, both financially and with regard to the patient's quality of life. It is estimated that the Medicare program spends one third of the cost of treating cancer in the final year of a patient's life and 78 % of that spending occurs in the final month \[[@CR49]\]. Broomberg \[[@CR33]\] argues that this is an expected result of incentives in fee-for-service payment systems, which reinforce doctors' tendency to apply health care resources inconsistently as they practice independently with few systems in place for developing treatment protocols and practice reviews. It follows that the payers queried in Greenapple's \[[@CR40]\] survey believe that replacing individual services with effective "bundles" of oncology care could bring down end-of-life costs while also improving quality and reducing regional variation.

Workload, recruitment, and retention are all affected by changes to physician payment models. Effects seem to be magnified in the specialist context as their several extra years of training lowers their supply to the system. Payment models that lead to poor retention of providers, for example, if remuneration does not cover physician costs as in the case of chemotherapy drug administration services \[[@CR35]\], may lead to heavy workloads which in turn complicate recruitment. Also it has been noted that the proportion of patients assigned "high-severity" status for accounting purposes can be significantly reduced when the workload of the discharging physician is increased, resulting in a substantial revenue loss for the hospital \[[@CR50]\]. However, few of the studies that focused on the specialist context examined workforce factors such as these as outcomes \[[@CR37]\]. Clearly, future studies aiming to evaluate the impact of changes to payment methods for oncologists in Canada should include measurement and analysis of changes in workload and workforce factors. Levels of hospital utilization and expenditures/claims are obvious starting points in areas where oncologists are primarily employed by hospitals. Yet in addition to these general indicators, payers may also be interested in changes in the likelihood of adverse events since these can have direct, predictable impacts on utilization and expenditure; hospital readmission rates could be used to proxy for adverse events. In terms of office-based oncologists, changes in the number of tests ordered after patient consultations could be examined. In both settings, conformity with guidelines for evidence-based medicine is a way to evaluate the impact of pay-for-performance payment systems.

It is also crucial to evaluate how much of the variation observed after a new payment method's implementation should be attributed to factors other than that method. A few studies took up this challenge. Kristiansen et al. \[[@CR39]\] report that the variables used in their analyses explain only 10 % of the observed variation in laboratory utilization; as a result, they note that the main determinant of test ordering behavior is probably the medical condition. This emphasizes the necessity of conducting studies in the cancer context: to discover factors that drive cost, but can be changed while controlling for unchanging disease complexity. It should also be noted that two studies \[[@CR14], [@CR38]\] used random sampling while others targeted a specific population and then included all or most members of the population who agreed to participate.

Many payers are experimenting with different payment strategies. However, some study results may not be generalizeable to other contexts, either because of the research methods or also the structure of the health system studied. An example of structural difference is the Taiwanese health system where doctors (including those at the primary care level) are almost all employed by hospitals \[[@CR32]\]. Reforms instituted at the hospital level may broadly affect physician behavior, but this will not be the case in systems where doctors practice independently. Another example is in single payer context where payment models may need to include specific reimbursement for teaching and research services \[[@CR36]\]. In multi-payer systems, having several funding streams may make these activities more likely to be funded by one of the payers. As experimentation continues, we should remember that most studies report short-term effects of payment system changes, but the longer term-associated changes in technology use and practice structure may be much larger in magnitude \[[@CR51]\]. For example Finkelstein \[[@CR52]\] has shown that the implementation of Medicare in 1965, which caused a large increase in fee-for-service reimbursement, led to much larger effects on cost, technology use, and practice delivery over time than was suggested by initial, static analyses.

This review experiences some methodological limitations common to rapid literature reviews. The lack of a systematic review process implies some study selection bias. Although we evaluate the credibility of study findings, we did not include a systematic quality assessment process; it has been argued that forgoing such a process is a source of bias in rapid reviews \[[@CR53]\]. However, the body of literature was so small that eliminating work based on a quality rubric would likely have left us too little to review. Another possible limitation is that we did not perform in-duplicate data extraction and post hoc data extraction review. Further, in the current policy environment, where as noted above the MACRA legislation is overhauling physician payment methods in the huge system of US Medicare, rapid reviews have an advantage over systematic reviews because they can be produced quickly to facilitate evidence-based policymaking.

The review includes only articles published in English. While limiting results in this way could omit Quebec-specific results, prior research \[[@CR54]\] shows that English-language-restricted literature searches tend to have similar results to those without language restrictions (when the review's content is mainly based within published literature). A follow-up gray literature search could be expanded to include French content.

Conclusions {#Sec18}
===========

This review presents currently published literature related to the impact physician payment method has on cancer care. It shows that, although general impacts of physician payment methods have been well-studied, research has seldom been extended to the specialized circumstances of cancer care.

Nevertheless, several findings have implications for decision-makers concerned with the impact of physician payment systems on cancer care. Patients with high-severity illnesses may receive too little treatment in bundled payment systems that rely on patient diagnosis so it may be prudent to invest in quality measurement programs when implementing these systems. Fee-for-service payment models can also lead to too little treatment when prices do not vary to account for patient status, e.g., when a treatment is not complex in principle, but it is made so by the overall poor health of the patient. However, we see that even high levels of treatment are not necessarily a corollary for quality of care, so even when fee-for-service incentivizes the provision of too much treatment, it may still need to incorporate quality measurement.

Cancer care is resource-intensive: technologies are expensive and treatments are time-intensive. The time is right to evaluate outcomes that occur before and after reforms to oncologist payment methods, for example, BC's recent move from fee-for-service to salary-based payment. Others could leverage the results of this experiment to avoid costly duplication. Recruitment and retention rates should also be examined to further quantify impacts of new programs; effects on research production and teaching programs are also of interest.
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